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Abstract
Objectives. To examine temporal trend in uptake of seasonal influenza vaccine (SIV) in the UK and explore disease and
demographic factors associated with vaccination.
Methods. From the Clinical Practice Research Datalink, 32 751 people with auto-immune rheumatic diseases pre-
scribed DMARDs between 2006 and 2016 were identified. The proportion vaccinated between 1 September of one year
and 31 March of the next year was calculated and stratified by age, other indications for vaccination, auto-immune
rheumatic diseases type and number of DMARDs prescribed. Stata and Joinpoint regression programs were used.
Results. SIV uptake was high in those aged565 years (82.3 and 80.7% in 200607 and 201516, respectively). It was
significantly lower in other age groups, but improved over time with 51.9 and 61.9% in the 4564 year age group, and
32.3 and 50.1% in the <45 year age group being vaccinated in 200607 and 201516, respectively. While 64.9% of the
vaccinations in those565 years old occurred by 3 November, in time to mount a protective immune response before the
influenza activity becomes substantial in the UK, only 38.9% in the 4564 year and 26.2% in the <45 year age group
without any other reason for vaccination received SIV by this date. Women, those with additional indications for vaccin-
ation, on multiple DMARDs and with SLE were more likely to be vaccinated.
Conclusion. SIV uptake is low in the under 65s, and the majority of them are not vaccinated in time. Additional effort is
required to promote timely uptake of SIV in this population.
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Rheumatology key messages
. Uptake of seasonal influenza vaccine is low in the absence of additional indications for vaccination.
. Most vaccinations do not occur in time before the flu virus begins to circulate.
. Young age seems to be an important barrier to seasonal influenza vaccination.
Introduction
Autoimmune rheumatic diseases (AIRDs) such as RA and
SLE associate with increased risk of influenza and its
complications [14]. This may be compounded by the
use of potent DMARDs and biologic agents [58]. The
EULAR and ACR recommend that people with AIRDs re-
ceive seasonal influenza vaccine (SIV) before commen-
cing a DMARD, and annually thereafter [9, 10]. In the
UK, SIV is recommended for people >65 years, the im-
munosuppressed and those at risk of influenza or its com-
plications [11], while universal vaccination is
recommended for adults in the USA [12].
The uptake of SIV in people with RA, the commonest
AIRD, is suboptimal. For instance, only 23.5% of people
with RA in the multinational COMObidities of Rheumatoid
Arthritis (COMORA) cohort received SIV with substantial
global variation (range 166.2%) [13]. Higher self-reported
vaccination rates (range 3777%) were reported in small
(n= 71155) hospital-based surveys from the UK [1419].
Similar small (n= 100137) single-centre hospital-based
studies from other European hospitals reported uptakes
of 2048% [2022]. A previous study using data from the
Clinical Practice Research Datalink (CPRD) reported that
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80% of incident RA cases on DMARDs receive at least
one SIV over a mean 5-year period, with 2131% of the
under 65 years and 5576% of those 65 years in age or
older receiving all expected vaccinations [23] This and
other small single-centre studies mostly include people
with RA, and a large study examining the uptake of SIV
in a range of AIRDs has not been performed. Similarly, it is
not known whether the uptake of SIV is improving and
whether people with AIRDs are vaccinated in time, that
is, at least 2 weeks before commencement of influenza
activity to allow time for seroconversion.
The overall aim of this study was to determine the
uptake of SIV in people with AIRDs treated with
DMARDs. The objectives of this study were to examine
(i) the temporal trend in SIV uptake between 200607 and
201516 influenza seasons, (ii) the proportion vaccinated
in time before the seasonal flu virus circulates in the com-
munity, (iii) factors associated with receiving SIV and
(iv) regional variation in vaccination in people with AIRDs
treated with DMARDs.
Methods
Data source
CPRD is a longitudinal database of the UK’s general prac-
tice (GP) medical records incepted in 1987. In July 2013,
684 GPs were contributing data to CPRD for over 11 mil-
lion anonymized patients [24]. People registered in the
CPRD are representative of the UK general population in
terms of age, sex and ethnicity. CPRD includes informa-
tion on demographics, lifestyle factors, diagnoses,
medications, results of investigations and examinations,
referral to hospitals, and prescribed medications.
Diagnoses in CPRD are recorded using Read codes, a
coded dictionary of clinical terms. The data undergo thor-
ough quality checks and are of a reliable research stand-
ard with a high validity of recorded diagnoses, including a
median proportion of cases with a confirmed diagnosis of
89% for 183 different conditions including chronic auto-
immune diseases [25]. Validation studies also confirm high
levels of completeness of clinical, diagnostic and pre-
scription data [25].
This study was approved by the Independent Scientific
Advisory Committee of the Medicines and Healthcare
Regulatory Authority (reference number: 16_288R).
Study population
Participants having one or more Read codes for RA, SLE
or spondyloarthropathy (SpA, defined as PsA, ReA, IBD-
associated arthritis or AS) and at least one prescription of
MTX, LEF, SSZ, AZA, ciclosporin, MMF or tacrolimus be-
tween 1 April 2006 and 31 March 2016 were included.
Identification of participants
Previously published Read code lists were used to identify
people with RA [26, 27]. Read code lists to identify par-
ticipants with SLE, ReA, IBD-associated arthritis, AS or
PsA were developed by G.N. (a post-doctoral research
fellow) A.A. (a rheumatologist) and C.D.M. (a general
practitioner). Similarly, product code lists were developed
to identify prescriptions of MTX, LEF, SSZ, AZA, ciclos-
porin, MMF and tacrolimus.
Entry into the study was considered as the latest of
DMARD prescription date, current registration date, or
1 April 2006. Study exit was the earliest of transfer out
date, date of death, date of last data collection from the
participants’ GP surgery or 31 March 2016.
Cohort building
The study period 1 April 2006 to 31 March 2016 was par-
titioned into ten 1-year seasonal episodes, beginning on 1
April of one year, and ending on March of the subsequent
year. Ten separate cohorts for each influenza season were
constructed, comprising people with AIRDs prescribed
DMARD(s). Inclusion criteria were age 518 years at the
start of the cohort, contributing data on 1 September of
that year (start of influenza season) with 53-month con-
tinuous registration at their current GP surgery prior to this
date, and DMARD prescription in this period. The 3-month
time lag was to allow the GP surgery time to include pa-
tients in any practice level at-risk register for influenza
vaccination.
Primary outcome
SIV administration was the primary outcome and was
defined using published product and Read code lists
[23]. For participants who had more than one entry for
SIV administration in an influenza season, the first vaccin-
ation record was considered valid. Vaccination status of
participants who contributed data to more than one influ-
enza season returned to unvaccinated on 1 April of the
subsequent year. Read codes for pandemic influenza vac-
cine were excluded as this study focused on temporal
trends in SIV uptake.
Secondary outcome
The secondary outcome was SIV administration by the
3rd November, that is, 9 weeks from 1 September. This
would allow the individual to mount a protective immune
response before mid-November when the influenza virus
begins to circulate in the UK [11].
Additional indications for SIV administration
Indications for SIV vary between countries. In the UK, SIV
is indicated in those >65 years, and in those with chronic
respiratory, heart, kidney, liver and neurological diseases,
immunosuppression or diabetes as they are at a high risk
of influenza and its complications [11]. Therefore, for this
study, participants were classified as having an additional
indication for vaccination if they were at least 65 years old,
or had another at-risk condition that mandates SIV admin-
istration apart from DMARD prescription at the start of the
influenza season. At-risk conditions were defined using
Read code lists developed by Costello et al. [23]. These
encompass chronic respiratory diseases, chronic heart
diseases, chronic kidney diseases, chronic liver diseases,
chronic neurological diseases, diabetes, immunosuppres-
sion and asplenia.
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Statistical analyses
The percentage and 95% CI of participants who received
SIV between 1 September of one year and 31 March of
the next calendar year (i.e. start and end of influenza
season) was calculated. This was stratified by age (<45,
4564, 565 years), presence of other indication for SIV
administration, type of AIRD (RA, SLE or SpA) and
number of DMARDs prescribed (1 or >1) at annual-
cohort entry. Percentage (95% CI) of vaccinations that
occurred by 3 November of a year was calculated. The
cumulative weekly uptake of SIV, stratified by age group
and presence of other at-risk conditions was plotted using
cumulative frequency curves.
Joinpoint analysis was used to determine the temporal
trend in SIV uptake between 200607 and 201516 influ-
enza seasons. This was stratified for age, AIRD type and
at-risk conditions for vaccination [11]. Joinpoint uses the
Bayesian information criterion to generate different num-
bers of joinpoints indicating points in time where trends in
SIV uptake change significantly and to fit separate linear
trends in each time segment. Annual percentage changes
for each segment and the overall annual percentage
changes (i.e. without any model fitted) were calculated.
Poisson regression with robust error variance was used
to examine the univariate and multivariate associations
between age, sex, AIRD type, at-risk conditions for vac-
cination, number of DMARDs prescribed in the preceding
12 months and receiving the SIV. A unique participant
identifier was incorporated as a clustering term in the
model [28]. Adjusted incidence rate ratios (aIRR) and
95% CI were calculated. This analysis was repeated
using data from participants exposed to methotrexate to
avoid confounding due to DMARD potency. The uptake of
SIV in each geographic regions of the UK during the
201516 season was calculated. Poisson regression
was used to examine the univariate and multivariate
association between regions and SIV administration, and
adjusted for age, sex, AIRD type, number of DMARDs
prescribed and at-risk conditions for influenza or its
complications. Data management and analysis were per-
formed in Stata version 14 (StataCorp, College Station,
TX, USA).
Results
Data from 32 751 people with AIRDs prescribed 51
DMARDs between 1 April 2006 and 31 March 2016 were
included. Their mean (S.D.) age at study entry was 58.17
(14.65) years and 65.70% were female. The mean (S.D.)
follow-up time was 4.37 (3.17) years. Of those included,
24 826 (75.80%) had RA, 6671(20.37%) had SpA and
1254 (3.83%) had SLE.
The overall uptake of SIV increased by 2.67%
(2.03.4%, P< 0.01) per year from 2006 to 2013 and re-
mained stable between 2013 and 2015 (Table 1, Fig. 1 and
supplementary Table S1, available at Rheumatology
online). On stratified analysis, the SIV uptake did not in-
crease in the over 65s (supplementary Table S1, available
at Rheumatology online). However, it increased in people
aged between 45 and 64 years, and in those <45 years
(supplementary Table S1, available at Rheumatology
online).
Just under half of all vaccinations (49.89%; 95% CI:
49.64, 50.14%) occurred by 3 November, that is, in time
before substantial influenza activity in the UK. The propor-
tion (95% CI) of vaccinations that happened in time was
64.93 (64.57, 65.30)% in the over 65s, 52.85 (52.01,
53.70)% and 38.89 (38.47, 39.31)% in those aged
4564 years with and without another at-risk condition
for flu vaccination, respectively, and 33.22 (31.21,
35.32)% and 26.18 (25.54, 26.84)% in those aged
45 years or younger, with and without another at-risk con-
dition for flu vaccination, respectively (Fig. 2). The uptake
of SIV was significantly higher in those with an additional
indication for vaccination (Figs 3 and 4 and supplementary
Tables S2 and S3, available at Rheumatology online).
Increasing age, female sex, presence of other at-risk
conditions and prescription of more than one DMARD
were independently associated with SIV administration
(Table 2). After adjusting for age, sex, study year, other
at-risk conditions and number of DMARDs prescribed,
SLE was significantly more, and SpA significantly less
likely to be associated with vaccination than RA
(Table 2). These results remained unchanged when the
analysis was restricted to influenza seasons with expos-
ure to methotrexate at the annual-cohort entry, except for
a lack of association between SLE and vaccination status
(supplementary Table S4, available at Rheumatology
online).
Geographic variation in SIV uptake was assessed in the
latest flu season. In the 201516 influenza season, the
uptake of SIV ranged between 62.58% in London and
77.74% in Scotland (supplementary Table S5, available
at Rheumatology online). Using Poisson regression
adjusted for age, sex and at-risk condition for flu vaccin-
ation, a statistically significant increased SIV uptake was
observed in Northern Ireland [aIRR (95% CI): 1.16 (1.03,
1.30)] and Scotland [aIRR (95% CI): 1.15 (1.05, 1.27) com-
pared with the South West of England (supplementary
Table S5, available at Rheumatology online). The South
West of England was used as the reference as this
region had the median SIV uptake among all regions of
the UK.
Discussion
This nationwide primary-care study of SIV uptake over
10 years in people with AIRDs treated with DMARDs dem-
onstrates an increase in uptake of SIV driven by improving
uptake in people aged <65 years. However, despite this,
the uptake of SIV in individuals <45 years, and in those
aged between 45 and 64 years without an at-risk condition
for vaccination remained significantly lower than the rec-
ommended 75% target of flu vaccination coverage for
people with at-risk conditions [2931]. Additionally, most
flu vaccinations in the under 65s did not occur in time, that
is, 2 weeks before the flu virus begins to circulate.
It is not possible to compare these findings with those
of previous studies, since, to our knowledge, this is the
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first study to assess temporal trend in uptake of SIV
among AIRDs and to compare uptake between different
AIRDs. However, when compared with the national flu
vaccination rates in England, the vaccine uptake in the
under 65s in our study was higher in the year 200607
(national SIV uptake: 42.10% vs SIV uptake in study:
44.80%) and improved further (in the year 201415 na-
tional SIV uptake: 50.30% vs SIV uptake in study:
63.73%) [11]. A similar trend was observed for vaccine
uptake in the over 65s, with 73.9 and 71.0% people in
England receiving SIV in 200607 and 201516, respect-
ively, compared with 82.3 and 80.7% in our study for the
same years. The trend towards a reduction in vaccine
uptake in the 201516 influenza season observed in this
study was mirrored in the nationwide data [11].
The trend of increasing SIV uptake may be explained by
greater public awareness, national campaigns, recom-
mendations [9, 10] and efforts of rheumatology multi-dis-
ciplinary teams in educating people with AIRDs and their
GPs about the need for SIV [1417]. There was a substan-
tial increase in SIV administration in the 201011 and
201112 flu seasons, especially in the <65 age group,
which could be related to the pandemic flu in the year
200910, which increased awareness of flu vaccination.
We observed that the uptake of SIV in those without an
additional reason for vaccination has improved over the
10-year period, but is still significantly lower than the
uptake in those 565 years or with other at-risk condi-
tions [11]. This accords with results of previous smaller
studies [1316, 1823, 32], and may reflect the fact that
immunosuppressive DMARDs for which seasonal flu
vaccination is indicated is left to individual doctors’ clin-
ical judgement, which may result in differential vaccine
access [11]. Thus, more needs to be done to improve SIV
uptake in this age group. As flu vaccinations occur in
primary care, there is a need to educate people with
AIRDs <65 years in age, as well as their GPs, about the
risks of influenza and its complications in the immuno-
suppressed [16, 32]. Such interventions are likely to in-
crease SIV uptake, as people with AIRDs cite lack of
awareness about increased risk of influenza, need for
influenza vaccination and not being offered the vaccine
as reasons for not being vaccinated [1416, 1820, 22,
32, 33]. Strategies to improve flu-vaccination uptake in-
clude face-to-face patient education or provision of writ-
ten educational materials [odds ratio (OR) = 1.113.33],
and financial incentives (OR = 2.22) or reminders (ORs =
2.033.03) directed at healthcare professionals (HCPs)
TABLE 1 Total population and percentage (95% CI) administered seasonal influenza vaccinea between 2006 and 2016
Year Overall Age 565 years
Age 4564 years,
at-risk condition
present
Age 4564 years,
at-risk condition
absent
Age <45 years,
at-risk condition
present
Age <45 years,
at-risk condition
absent
200607 13 805 5658 1054 5078 192 1823
61.52
(60.71, 62.33)
82.33
(81.31, 83.30)
69.07
(66.21, 71.79)
48.39
(47.01, 49.76)
46.35
(39.40, 53.45)
30.77
(28.70, 32.93)
200708 14 663 6073 1168 5355 191 1876
62.11
(61.32, 62.89)
81.67
(80.68, 82.63)
69.43
(66.73, 72.01)
49.23
(47.89, 50.56)
46.07
(39.11, 53.19)
32.62
(30.54, 34.78)
200809 15 377 6468 1288 5849 209 1923
64.04
(63.28, 64.80)
81.79
(80.83, 82.71)
71.12
(68.58, 73.53)
51.76
(50.43, 53.08)
48.33
(41.61, 55.11)
36.40
(34.28, 38.58)
200910 15 904 6775 1378 5572 218 1961
64.60
(63.85, 65.34)
80.80
(79.84, 81.72)
69.38
(66.89, 71.76)
53.02
(51.70, 54.32)
49.08
(42.49, 55.71)
39.93
(37.78, 42.12)
201011 17 013 7170 1475 6029 236 2103
67.10
(66.39, 67.80)
81.72
(80.80, 82.59)
73.02
(70.69, 75.22)
57.62
(56.37, 58.86)
58.05
(51.64, 64.20)
41.32
(39.23, 43.44)
201112 16 430 7229 1447 5643 219 1892
71.23
(70.53, 71.92)
82.99
(82.10, 83.83)
76.36
(74.11, 78.48)
62.77
(61.50, 64.02)
56.62
(49.96, 63.05)
49.31
(47.06, 51.57)
201213 16 563 7409 1489 5587 224 1854
72.30
(71.61, 72.78)
83.53
(82.67, 84.36)
78.84
(76.70, 80.85)
63.24
(61.96, 64.49)
61.61
(55.06, 67.76)
50.76
(48.48, 53.03)
201314 15 879 7236 1571 5140 223 1709
72.35
(71.65, 73.04)
84.41
(83.56, 85.23)
76.38
(74.22, 78.42)
62.24
(60.90, 63.55)
60.09
(53.51, 66.33)
49.62
(47.25, 51.99)
201415 14 593 6784 1373 4786 178 1472
72.41
(71.68, 73.13)
82.40
(81.47, 83.29)
77.57
(75.28, 79.70)
63.66
(62.29, 65.02)
57.87
(50.47, 64.92)
51.77
(49.21, 54.31)
201516 12 252 5717 1114 4049 135 1237
69.38
(68.55, 70.19)
80.74
(79.70, 81.74)
72.26
(69.56, 74.81)
59.08
(57.55, 60.58)
60.00
(51.49, 67.94)
48.99
(46.21, 51.78)
aVaccination period taken as from 1 September to 31 March.
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[34]. Interestingly, educational outreach/feedback dir-
ected at HCPs did not improve uptake of SIV [OR (95%
CI): 0.77 (0.72, 0.81)], whereas improving vaccine access
with home visits or free vaccinations did improve the
uptake (ORs = 1.301.98) [34]. Other factors such as
having a lead HCP responsible for flu-vaccination in a
GP surgery, robust IT systems to identify people at risk
of flu and its complications, reminding HCPs about SIV
and sending personal invitations and reminders, includ-
ing telephone reminders to patients, associated with
FIG. 1 Uptake of seasonal influenza vaccine in immunosuppressed AIRD patients (200616)
Percentage of people with autoimmune rheumatic diseases on DMARD vaccinated in each flu season from 2006 to 2016.
AIRD: autoimmune rheumatic diseases.
FIG. 2 Cumulative seasonal influenza vaccine uptake between the September and March in all influenza seasons
Weekly cumulative seasonal influenza vaccine uptake between 1 September and 31 March in all influenza seasons.
Overall vaccine uptake was significantly higher in the over 65s (P < 0.001) and 4564 year (P < 0.001) age group with
another at-risk condition for vaccination than the 4564 year age group without another at-risk condition for vaccination
(reference group). The latter had statistically similar vaccination rates to people <45 years in age with another at-risk
condition for vaccination (P = 0.267), while those <45 years without another at-risk condition for vaccination had sig-
nificantly lower vaccination uptake than the reference group (P < 0.001).
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improved SIV uptake in a survey of 795 GP surgeries
across England [35].
The ideal time for influenza vaccination in the UK is be-
tween September and early November, allowing 2 weeks
for the immune response to be achieved before influenza
activity becomes significant [11]. Our results, however,
reveal delayed uptake of vaccination, especially in the
under 65s and in those without another at-risk condition
FIG. 3 Uptake of seasonal influenza vaccine in immunosuppressed AIRD patients by disease type (200616)
Percentage of people with AIRD on disease modifying anti-rheumatic drugs vaccinated in each flu season from 2006 to
2016 according to individual AIRD. AIRD: autoimmune rheumatic diseases.
FIG. 4 Uptake of seasonal influenza vaccine in immunosuppressed AIRD patients by number of DMARDs (200616)
Percentage of people with AIRD on disease modifying anti-rheumatic drugs vaccinated in each flu season from 2006 to
2016 according to number of different types of DMARDs at the start of flu season. AIRD: autoimmune rheumatic
diseases.
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for receiving SIV. This is contrary to the findings of a
claims database study from Germany in which 95% of
participants who received SIV did so by November [4].
Thus, people with AIRDs and their GPs should be espe-
cially reminded about SIV in autumn months [35].
The uptake of SIV was significantly higher in people
aged 565 years, and was more than the target for vac-
cination coverage set by the Department of Health, the
European Council and the WHO. This may be driven by
the Quality and Outcome Framework that has provided
financial incentives to GP surgeries for administering flu
vaccination to people aged 565 years since the
19992000 influenza season. It resulted in a substantial
increase in vaccination rates within 1 year [36]. Other fac-
tors such as a high burden of co-morbidities and availabil-
ity of time may also have contributed. A previous study
from Germany also demonstrated increasing SIV uptake
with increasing age [4].
Our study revealed variations in the uptake of influenza
vaccination according to AIRD type, with lower uptake in
SpA. This was present on sensitivity analysis, restricting to
influenza seasons in which a MTX prescription was
issued. This suggests that greater effort should be em-
ployed to improve vaccination rates in people with SpA,
who are predominantly male and less likely to seek pre-
ventive measures.
There are several caveats to our study. Firstly, some flu
vaccinations may have been administered in a hospital or
at the work-place, for example, vaccinations in health care
professionals. This is unlikely to have a significant impact
as SIV is administered predominantly in primary care in
the UK, and Read codes that indicate SIV administration
outside the GP surgery, that is, in a hospital, place of work
or privately, were included in the code list. Moreover, we
excluded small vessel vasculitis because of the rarity of its
recording in the CPRD [37]. Similarly, given their extremely
rare use in modern rheumatology practice, we excluded
penicillamine and gold prescriptions. Finally, the data on
prescription of biologic agents is not recorded in the
CPRD, and for this reason we cannot compare SIV
uptake in those prescribed biologic and conventional
DMARDs. However, a previous German study did not
report higher SIV uptake in people on biologic DMARDs
compared with conventional DMARDs [4].
There are several strengths of this study, which include
a large nationally representative sample size, use of a
combination of diagnostic Read codes and DMARD pre-
scriptions to identify immunosuppressed people with
AIRDs, inclusion of a broad spectrum of AIRDs and a lon-
gitudinal observation period of 10 years. Use of primary
care prescription and consultation data minimizes the
risk of recall bias associated with questionnaire surveys.
In summary, this study demonstrates improving but still
low uptake of SIV in people with AIRDs <65 years.
Similarly, the majority of people in this age group are vac-
cinated after the seasonal flu virus begins to circulate.
Thus, rheumatologists and GPs should particularly edu-
cate younger people with AIRDs about the need for timely
annual seasonal flu vaccination.
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TABLE 2 Disease and demographic characteristics asso-
ciated with seasonal influenza vaccine administration
Risk factors
Crude IRR
(95% CI)
Adjusted IRR
(95% CI)a
Age, years
<45 1 1
4564 1.35 (1.32, 1.39) 1.33 (1.29, 1.36)
565 1.81 (1.77, 1.86) 1.73 (1.68, 1.77)
Sex
Male 1 1
Female 1.04 (1.03, 1.06) 1.03 (1.02, 1.05)
AIRD type
RA 1 1
SLE 0.92 (0.88, 0.95) 1.06 (1.02, 1.10)
Seronegative
spondyloarthropathy
0.81 (0.80, 0.83) 0.93 (0.92, 0.95)
Number of DMARDs
1 1 1
52 1.07 (1.05, 1.09) 1.08 (1.07, 1.10)
Other influenza at-risk conditions
Absent 1 1
Present 1.23 (1.22, 1.25) 1.12 (1.11, 1.13)
aAdjusted for study year and other variables in the table.
AIRD: autoimmune rheumatic diseases; IRR: incidence rate
ratio.
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Supplementary data
Supplementary data are available at Rheumatology online.
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